Search Result

Results for "

G1 and S-phases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ACSL Family (1) Akt (3) Anaplastic lymphoma kinase (ALK) (2) Apoptosis (29) Aryl Hydrocarbon Receptor (1) Atg7 (1) Atg8/LC3 (2) Autophagy (9) Bcl-2 Family (2) Btk (1) c-Kit (1) c-Met/HGFR (1) Cannabinoid Receptor (1) Carbonic Anhydrase (2) Casein Kinase (1) Caspase (4) CD74 (1) CDK (10) Checkpoint Kinase (Chk) (1) Cytochrome P450 (1) Deubiquitinase (2) Dihydrofolate reductase (DHFR) (2) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (3) Drug Metabolite (2) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (1) Early 2 Factor (E2F) (1) EGFR (5) Environmental Pollutants (1) ERK (3) Fatty Acid Synthase (FASN) (2) Ferroptosis (2) GLUT (1) Glutathione Peroxidase (1) HDAC (3) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) HIV Protease (2) HSP (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Interleukin Related (1) Isotope-Labeled Compounds (1) MDM-2/p53 (3) Melanocortin Receptor (2) Microtubule/Tubulin (2) MMP (1) Molecular Glues (6) mTOR (3) NF-κB (1) Oct3/4 (1) Orexin Receptor (OX Receptor) (1) PARP (1) Phosphatase (3) Phospholipase (2) PI3K (1) Pim (2) PINK1/Parkin (1) PROTACs (3) Proteasome (1) Raf (1) Reactive Oxygen Species (ROS) (4) Reference Standards (1) ROS Kinase (1) SARS-CoV (1) Sirtuin (2) SOD (1) Stearoyl-CoA Desaturase (SCD) (1) Survivin (1) TNF Receptor (1) Topoisomerase (5) Trk Receptor (1) TRP Channel (1) VEGFR (4) Wee1 (1)
By Research Areas:	Cancer (63) Cardiovascular Disease (1) Endocrinology (1) Infection (4) Inflammation/Immunology (6) Metabolic Disease (4) Neurological Disease (5)

By Targets:

ACSL Family (1)

Akt (3)

Anaplastic lymphoma kinase (ALK) (2)

Apoptosis (29)

Aryl Hydrocarbon Receptor (1)

Atg7 (1)

Atg8/LC3 (2)

Autophagy (9)

Bcl-2 Family (2)

Btk (1)

c-Kit (1)

c-Met/HGFR (1)

Cannabinoid Receptor (1)

Carbonic Anhydrase (2)

Casein Kinase (1)

Caspase (4)

CD74 (1)

CDK (10)

Checkpoint Kinase (Chk) (1)

Cytochrome P450 (1)

Deubiquitinase (2)

Dihydrofolate reductase (DHFR) (2)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (3)

Drug Metabolite (2)

Drug-Linker Conjugates for ADC (1)

E1/E2/E3 Enzyme (1)

Early 2 Factor (E2F) (1)

EGFR (5)

Environmental Pollutants (1)

ERK (3)

Fatty Acid Synthase (FASN) (2)

Ferroptosis (2)

GLUT (1)

Glutathione Peroxidase (1)

HDAC (3)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Methyltransferase (1)

HIV Protease (2)

HSP (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

MDM-2/p53 (3)

Melanocortin Receptor (2)

Microtubule/Tubulin (2)

MMP (1)

Molecular Glues (6)

mTOR (3)

NF-κB (1)

Oct3/4 (1)

Orexin Receptor (OX Receptor) (1)

PARP (1)

Phosphatase (3)

Phospholipase (2)

PI3K (1)

Pim (2)

PINK1/Parkin (1)

PROTACs (3)

Proteasome (1)

Raf (1)

Reactive Oxygen Species (ROS) (4)

Reference Standards (1)

ROS Kinase (1)

SARS-CoV (1)

Sirtuin (2)

SOD (1)

Stearoyl-CoA Desaturase (SCD) (1)

Survivin (1)

TNF Receptor (1)

Topoisomerase (5)

Trk Receptor (1)

TRP Channel (1)

VEGFR (4)

Wee1 (1)

By Research Areas:

Cancer (63)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (4)

Inflammation/Immunology (6)

Metabolic Disease (4)

Neurological Disease (5)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13817

IU1 20+ Cited Publications	Deubiquitinase Autophagy Apoptosis	Cardiovascular Disease Neurological Disease Endocrinology Cancer
IU1 is a selective, reversible USP14 inhibitor with an IC₅₀ of 4-5 μM. IU1 binds USP14’s catalytic cleft to block deubiquitinase activity. IU1 induces calpain-dependent Tau cleavage, causes ATP deficits, reduces E1~Ub thioester levels and 26S proteasome assembly. IU1 enhances 26S proteasome chymotrypsin-like activity, modulates LC3B-dependent autophagy flux, reduces cancer cell proliferation and migration, and blocks G0/G1 to S phase cell cycle transition in follicular thyroid cancer cells. IU1 activates autophagy-lysosomal and ubiquitin-proteasome pathways, triggers apoptosis, and reduces cervical cancer cell growth. IU1 enhances degradation of proteasome substrates linked to neurodegenerative disease, accelerates oxidized protein degradation, and increases oxidative stress resistance. IU1 can be used for the research of Alzheimer’s disease, follicular thyroid cancer, ischemic stroke, cervical cancer, and neurodegenerative disease .

HY-158106

AZD8421 1 Publications Verification	CDK	Cancer
AZD8421 is a selective CDK2 inhibitor (IC₅₀ = 9 nM) as well as achieving CDK family selectivity in cells versus key off-targets (CDK1, CDK4/6, CDK9), AZD8421 had no significant kinase inhibition outside the CDK family. AZD8421 inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest in G1/S phase and senescence. AZD8421 can be studied in research for breast cancer and ovarian cancer .

HY-13768

Topotecan Maximum Cited Publications 38 Publications Verification SKF 104864A; NSC 609669	Topoisomerase Autophagy Apoptosis	Cancer
Topotecan (SKF 104864A; NSC 609669) is an orally active and potent Topoisomerase I inhibitor. Topotecan induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan shows anticancer activity .

HY-N5074

Terrestrosin D	Apoptosis VEGFR	Inflammation/Immunology Cancer
Terrestrosin D is an orally active apoptosis inducer. Terrestrosin D induces cell cycle arrest at the G1 and S phases, reduces mitochondrial membrane potential, and inhibits the growth of cancer cells and endothelial cells. Terrestrosin D is studied in castration-resistant prostate cancer and pulmonary fibrosis .

HY-13721

Phenoxodiol 3 Publications Verification Idronoxil; Dehydroequol; Haginin E	Caspase Apoptosis Topoisomerase	Cancer
Phenoxodiol (Idronoxil), a synthetic analog of Genestein, activates the mitochondrial caspase system, inhibits XIAP (an apoptosis inhibitor), and sensitizes the cancer cells to Fas-mediated apoptosis. Phenoxodiol also inhibits DNA topoisomerase II by stabilizing the cleavable complex. Phenoxodiol induces cell cycle arrest in the G1/S phase of the cell cycle and upregulates p21 ^WAF1 via a p53 independent manner .

HY-17026E

Gemcitabine triphosphate trisodium dFdCTP trisodium	Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Gemcitabine triphosphate (dFdCTP) trisodium is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate trisodium cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate trisodium shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate trisodium partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate trisodium disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate trisodium can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-125098

Illudin S 1 Publications Verification	DNA Alkylator/Crosslinker Apoptosis	Infection Cancer
Illudin S, a cytotoxic Illudin, is a natural sesquiterpene with strong anti-tumour and antiviral activities. Illudin S has genotoxic activities. Illudin S blocks the G1-S phase interface of the cell cycle in human leukemia cells .

HY-17026A

Gemcitabine triphosphate dFdCTP	Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Gemcitabine triphosphate (dFdCTP) is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-113638

CVT-11127 GS-456332	Stearoyl-CoA Desaturase (SCD) Apoptosis	Cancer
CVT-11127 is a potent SCD inhibitor. CVT-11127 induces apoposis and arrests the cell cycle at the G1/S phase. CVT-11127 has the potential for the research of lung cancer .

HY-118672

HNHA	HDAC MMP HIF/HIF Prolyl-Hydroxylase	Cancer
HNHA is a potent HDAC inhibitor with an IC₅₀ of 100 nM. HNHA arrests the cell cycle at the G1/S phase via p21 induction. HNHA inhibits tumor growth and tumor neovascularization. HNHA may be a potent anti-cancer agent against breast cancer .

HY-145963

DRB18 1 Publications Verification	GLUT	Cancer
DRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity .

HY-124211

Dibenzo(a,i)pyrene	Environmental Pollutants MDM-2/p53 Aryl Hydrocarbon Receptor	Cancer
Dibenzo (a,i) pyrene is a polycyclic aromatic hydrocarbon and also a carcinogenic ligand of the TCDD (Ah) receptor. Dibenzo (a,i) pyrene binds to the TCDD (Ah) receptor in rat liver. Dibenzo (a,i) pyrene induces DNA adduct formation and upregulates the protein levels of p53 and p21 ^WAF1 in diploid lung fibroblasts. Dibenzo (a,i) pyrene alters the cell cycle distribution of diploid lung fibroblasts, increasing the proportion of cells in the S phase, decreasing the proportions of cells in the G0/G1 and G2/M phases, and causing S phase delay/arrest. Dibenzo (a,i) pyrene is applicable for cancer research .

HY-P1726

MSG606	Melanocortin Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
MSG606 is a selective melanocortin 1 receptor (MC1R) antagonist. MSG606 can abolish the neuroprotective effects of BMS-470539 (HY-15616) (MC1R agonist). MSG606 can inhibit cancer cell proliferation and transition from the G1 to the S phase. MSG606 can delay pain hypersensitivity and reduce cholesterol levels. MSG606 can be used for the researches of cancer, inflammation, neurological and metabolic disease, such as breast cancer and subarachnoid hemorrhage (SAH) .

HY-153803

GBD-9	PROTACs Molecular Glues Btk	Cancer
GBD-9 is a degrader based on the E3 ubiquitin ligase CRBN that targets BTK and the G1 to S phase transition protein GSPT1. GBD-9 has both PROTAC and molecular glue properties by inducing ubiquitination and proteasomal degradation of target proteins. GBD-9 can efficiently degrade wild-type and mutant BTK (such as C481S mutation) and GSPT1. GBD-9 significantly inhibits tumor cell proliferation by inducing G1 phase arrest in cancer cells, downregulating anti-apoptotic proteins (BCL-2, MCL-1) and activating Caspase-3 to induce apoptosis. GBD-9 is mainly used in the research of hematological tumors such as diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML) . GBD-9 is composed of E3 ubiquitin ligase ligand (pink part) 5-Aminothalidomide (HY-W023573), target protein ligand (blue part) Btk Inhibitor: IBT6A (HY-13036A), and PROTAC linker (black part) Nonanoic acid (HY-N7057).

HY-N1196

Suberosin	NF-κB	Inflammation/Immunology
Suberosin, isolated from Plumbago zeylanica, exhibits anti-inflammatory and anticoagulant activity. Suberosin suppresses PHA-induced PBMC proliferation and arrested cell cycle progression from the G1 transition to the S phase through the modulation of the transcription factors NF-AT and NF-κB .

HY-103333

Arvanil N-Vanillylarachidonamide	TRP Channel Cannabinoid Receptor CD74 Akt Orexin Receptor (OX Receptor)	Neurological Disease Inflammation/Immunology
Arvanil (N-Vanillylarachidonamide) is a mixed agonist of CB1 and TRPV1 receptors. Arvanil downregulates CD25, HLA-DR, CD134/OX40, blocks G1/S phase transition, and induces phosphorylation of Akt. Arvanil does not induce apoptosis in cells. Arvanil inhibits lymphocyte activation and ameliorates autoimmune encephalomyelitis. Arvanil can be used in research related to Huntington's disease, vomiting, and multiple sclerosis .

HY-N3389

Licoisoflavone A 2 Publications Verification	SARS-CoV Sirtuin CDK Apoptosis	Infection Metabolic Disease Cancer
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and SARS-CoV-2 infection .

HY-151978

ZC0109	Indoleamine 2,3-Dioxygenase (IDO) Apoptosis	Cancer
ZC0109 is a dual inhibitor of IDO1 and thioredoxin reductase 1 (TrxR1) with IC₅₀s of 50 nM and 3.0 μM, respectively. ZC0109 induces ROS accumulation and cell cycle arrest at G1/S phase, thus leads to cancer cells apoptosis .

HY-171825

SIAIS001	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
SIAIS001 is a CRBN-dependent ALK PROTAC degrader with a DC₅₀ of 3.9 nM. SIAIS001 induces ALK protein degradation via the ubiquitin-proteasome system. SIAIS001 induces G1/S phase cell cycle arrest and inhibits proliferation of cancer cells. SIAIS001 can be used for the research of anaplastic large-cell lymphomas .

HY-146887

USP7-IN-9	Deubiquitinase Apoptosis	Cancer
USP7-IN-9 is a highly potent ubiquitin-specific protease 7 (USP7) inhibitor with an IC₅₀ value of 40.8 nM. USP7-IN-9 can induce apoptosis and arrest cell progression at G0/G1 and S phases in RS4; 11 cells. USP7-IN-9 reduces the protein levels of oncoproteins MDM2 and DNMT1 and increases the protein levels of tumor suppressors p53 and p21 .

HY-135564A

RK-682	Phosphatase Phospholipase HIV Protease ERK Autophagy	Infection Cancer
RK-682 is the inhibitor for protein tyrosine phosphatase (PTPase), heparanase, phospholipase A2 and HIV-1 protease. RK-682 inhibits the dephosphorylation of CD45 (IC₅₀ is 54 μM) and VHR (IC₅₀ is 2.0 μM), and thereby inhibits the ERK signaling pathway. RK-682 inhibits the cell viability of cancer cell MGH-U3, T24 and UROtsa with IC₅₀s of 78.2, 43.2 and 145 nM, respectively, arrests the cell cycle at G1/S phase, inhibits the cell migration and autophagy in MGH-U3 and T24 .

HY-170405

YB-3–17	PROTACs mTOR	Cancer
YB-3-17 is a bifunctional molecule, that inhibits mTOR (IC₅₀=0.22 nM) or degrades *G1 to S phase* transition 1 gene (GSPT1, DC₅₀=5 nM) in a PROTAC mechanism. YB-3-17 exhibits antiproliferative activity in multi glioblastoma cell lines with IC₅₀** of nanomolare levels. YB-3-17 exhibits antitumor efficacy in mouse models . (Pink: ligand for target protein (HY-170407); Black: linker (HY-A0102); Blue: ligand for E3 ligase Cereblon (HY-14658))

HY-201330

GDC-4198 RGT-419B	CDK	Cancer
GDC-4198 (RGT-419B) is an orally active CDK4/2 inhibitor with desired degrees of selectivity against kinases such as CDK6, CDK9 and GSK3β. GDC-4198 inhibits the activity of cyclin-CDK complexes, blocks phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle transition from G1 to S phase. GDC-4198 is promising for research of cancers, such as breast cancer (especially hormone receptor-positive, HER2-negative type), lung cancer, and colorectal cancer .

HY-145670

cis,trans-Germacrone	Akt MDM-2/p53	Cancer
cis,trans-Germacrone is a isomer of Germacrone (HY-N0440). Germacrone exhibits a wide range of antitumor, antioxidant and anti-inflammatory effects. Germacrone inhibits lung cancer cell proliferation and alters the Akt/MDM2/p53. Germacrone also arrests cell cycle at G1/S phase .

HY-175810

GSPT1 degrader-8	Molecular Glues	Cancer
GSPT1 degrader-8 is a potent and orally active G1 to S phase transition 1 (GSPT1) molecular glue degrader. GSPT1 degrader-8 induces GSPT1 degradation and inhibits tumor growth. GSPT1 degrader-8 can be used for the research of cancer, such as breast cancer .

HY-170992

Autophagy agonist-1	Autophagy CDK Atg8/LC3 PINK1/Parkin	Cancer
Autophagy agonist-1 (compound 22) is an Autophagy agonist. Autophagy agonist-1 exhibits significant anticancer activity against HepG2 cells and normal cells with IC₅₀s of 8.8 μM and > 50 μM. Autophagy agonist-1 induces G1/S phase cell cycle arrest and inhibits CDK4 and CyclinD1 expression while upregulating P21. Autophagy agonist-1 promotes the accumulation of autophagosomes and the proteins LC3 and PINK1, enhancing autophagy and mitophagy in HepG2 cells .

HY-175819

PD-166285	Wee1 Apoptosis	Cancer
PD-166285 is a PKMYT1 inhibitor, with an IC₅₀ value of 17 nM. PD166285 shows strong antiproliferative effects against CCNE1-amplified OVCAR3 cells (IC₅₀ = 0.14 μM) and HCC1569 cells (IC₅₀ = 0.21 μM). PD166285 induces apoptosis and arrests CCNE1-amplified HCC1569 cells at the G1/S phase of the cell cycle. PD166285 can be used for the research of PKMYT1-targeted therapies for CCNE1-amplified cancers .

HY-114338B

Dalpiciclib isethionate SHR-6390 isethionate	CDK	Cancer
Dalpiciclib (isethionate) is a CDK4/6 inhibitor. Dalpiciclib (isethionate) inhibits the kinase activity of CDK4 and CDK6, thereby blocking the G1-to-S phase transition of the cell cycle and suppressing abnormal cell proliferation. Dalpiciclib (isethionate) can be used for the study of breast cancer .

HY-161780

Maleimide-PEG8-Val-Ala-PAB-SNS032	Drug-Linker Conjugates for ADC CDK	Cancer
Maleimide-Val-Ala-PAB-SNS032 is a conjugate of ADC toxin and linker. SNS032 is an inhibitor for CDK, inhibiting the cell cycle at G1/S phase and cell viability of cancer cells. Maleimide-Val-Ala-PAB is a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 can be utilized for the synthesis of ADC molecules .

HY-156470

Multi-kinase-IN-6	Trk Receptor Anaplastic lymphoma kinase (ALK) c-Kit EGFR Pim Casein Kinase Checkpoint Kinase (Chk) CDK Apoptosis	Cancer
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that shows good enzyme inhibitory activity against TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. Multi-kinase-IN-6 reveals antiproliferative activity against MCF7, HCT116 and EKVX with IC₅₀ values of 3.36 μM, 1.40 μM and 3.49 μM, respectively. Multi-kinase-IN-6 shows cell cycle arrest at the G1/S phase and G1 phase in MCF7 and HCT116 cells with good apoptotic effect .

HY-159609

GSPT1 degrader-9	Molecular Glues	Cancer
GSPT1 degrader-9 (Compound F) is a cereblon-based molecular glue degrader for *G1 to S phase* transition protein 1 (GSPT1) that degrades GSPT1 with a rate of 95% (1 μM) GSPT1 and 86% (0.1 μM). GSPT1 degrader-9 inhibits the cell viability of HL-60 with an IC₅₀** of 9.2 nM .

HY-177766

GSPT1 degrader-17	Molecular Glues Apoptosis	Cancer
GSPT1 degrader-17 (Compound 9q) is a potent and selective cereblon-based molecular glue degrader that targets *G1 to S phase* transition 1 (GSPT1). GSPT1 degrader-17 degrades GSPT1 in U937 cells with a DC₅₀ of 35 nM and Dmax of 81.65%. GSPT1 degrader-17 has a strong inhibitory effect on U937, MOLT-4 and MV4-11 cells with IC₅₀ values of 0.019, 0.006 and 0.027 μM. GSPT1 degrader-17 can induce cells apoptosis** and G0/G1 phase arrest. GSPT1 degrader-17 can be used for the research of cancer, such as acute myeloid leukemia .

HY-177724

GSPT1 degrader-11	Molecular Glues	Cancer
GSPT1 degrader-11 is a CRBN-dependent *G1 to S phase* transition 1 (GSPT1) molecular glue degrader (DC₅₀ = 67.7 nM, D_max = 97%). GSPT1 degrader-11 can inhibit MDA-MB-231 CRBN-WT cells proliferation (IC₅₀** = 2.07 μM). GSPT1 degrader-11 can be used for the research of cancer .

HY-W025074

BML-278	Sirtuin Histone Methyltransferase	Cancer
BML-278 is a SIRT1 activator (EC₁₅₀: 1 μM). BML-278 increases H3K9 methylation and inhibits H3K9 acetylation in both the paternal and maternal pronucleus. BML-278 improves early embryonic development. BML-278 arrests the cell cycle at the G1/S phase, and reduces senescence in primary human mesenchymal cells. BML-278 reduces tubulin acetylation in U937 cells. BML-278 also increases mitochondrial density in murine C2C12 myoblasts .

HY-177765

GSPT1 degrader-16	Molecular Glues	Cancer
GSPT1 degrader-16 (Compound Lib-B-18J) is a potent and selective cereblon-based molecular glue degrader that targets *G1 to S phase* transition 1 (GSPT1). GSPT1 degrader-16 shows inhibitory effect to RS4;11, Molt4, and MM.1S cells with IC₅₀** values of 0.002, 0.26 and 0.37 μM. GSPT1 degrader-16 can be used for the research of cancer, such as acute lymphoblastic leukemi .

HY-P1726A

MSG606 TFA	Melanocortin Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
MSG606 TFA is a selective melanocortin 1 receptor (MC1R) antagonist. MSG606 TFA can abolish the neuroprotective effects of BMS-470539 (HY-15616) (MC1R agonist). MSG606 TFA can inhibit cancer cell proliferation and transition from the G1 to the S phase. MSG606 TFA can delay pain hypersensitivity and reduce cholesterol levels. MSG606 TFA can be used for the researches of cancer, inflammation, neurological and metabolic disease, such as breast cancer and subarachnoid hemorrhage (SAH) .

HY-174302

PIM-1/HDAC-IN-2	Pim HDAC PARP Apoptosis	Cancer
PIM-1/HDAC-IN-2 is a robust PIM/HDAC inhibitor (IC₅₀ = 0.11 μM in MV4-11cells), which exerts a synergistic antiproliferative effect through a dual mechanism of inhibiting PIM1 kinase and selectively inhibiting HDAC6. PIM-1/HDAC-IN-2 induces cell apoptosis. PIM-1/HDAC-IN-2 remarkably induces the cleavage of PARP, thereby initiating the arrest of the cell cycle in G1 phase and a reduction in S phase. PIM-1/HDAC-IN-2 demonstrates significant anticancer efficacyin the MV4-11 xenograft model without notable toxicity^[1]_.

HY-129108

9-cis-UAB30 (9Z)-UAB-30	Oct3/4 Microtubule/Tubulin E1/E2/E3 Enzyme Proteasome	Neurological Disease Cancer
9-cis-UAB30 is a rexinoid agonist. 9-cis-UAB30 significantly decreases the proliferation, viability, and motility of both patient-derived xenografts (PDXs). 9-cis-UAB30 induced cell-cycle arrest as demonstrated by the significant increase in the percentage of cells in G1 and a decrease in the percentage of cells in S phase by downregulating SKP2 and/or 20S proteasome activity, which leads to increased p27kip1 protein stability. 9-cis-UAB30 downregulates the abundance of stem cell marker mRNAs (Oct4, Nanog, Sox2, nestin) and upregulates the abundance of differentiation marker mRNAs (β3-tubulin, NSE, HOXC9, GAP43). 9-cis-UAB30 has no adverse effects on the central nervous system and cardiovascular system at the tested dose. 9-cis-UAB30 can be used for the study of neuroblastoma, cutaneous T-cell lymphomas, and breast cancer .

HY-13768C

Topotecan hydrochloride hydrate SKF 104864A hydrochloride hydrate; NSC 609669 hydrochloride hydrate	Topoisomerase Apoptosis Autophagy	Cancer
Topotecan hydrochloride hydrate is an orally active and potent Topoisomerase I inhibitor. Topotecan hydrochloride hydrate induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan hydrochloride hydrate shows anticancer activity .

HY-152135

TJ08	Apoptosis	Cancer
TJ08, a 1,2,5-trisubstituted benzimidazole derivative, efficiently induces G1/S phase arrest and promotes apoptosis in various cancer cells. TJ08 is an anticancer agent .

HY-163722

EGFR/DHFR-IN-1	EGFR Dihydrofolate reductase (DHFR)	Cancer
EGFR/DHFR-IN-1 (Compound 10e) is a dual inhibitor of EGFR and DHFR with IC₅₀s of 0.151 and 0.541 µM, respectively. EGFR/DHFR-IN-1 arrests the cell cycle at both G0-G1 and S phases .

HY-155055

Antiproliferative agent-26	Reactive Oxygen Species (ROS)	Cancer
Antiproliferative agent-26 (compound 4g) is an antiproliferative agent with much broad range of activity targeting Leukemia, CNS, Melanoma, Renal and Breast (at the concentration of 10 μM). Antiproliferative agent-26 inhibits colony forming and arrests cell cycle at G1 phase/S phase at 5 μM and 25 μM, respectively .

HY-146038

Antitumor agent-55	Apoptosis ROS Kinase MDM-2/p53 Bcl-2 Family	Cancer
Antitumor agent-55 (compound 5q) is a potent antitumor agent. Antitumor agent-55 effectively inhibits PC3, with an IC₅₀ of 0.91 μM. Antitumor agent-55 effectively inhibits the colony formation, suppresses the cell migration in PC3. Antitumor agent-55 induces G1/S phase arrest and apoptosis in PC3 .

HY-146491

VEGFR-2/BRAF-IN-1	VEGFR Raf Apoptosis	Cancer
VEGFR-2/BRAF-IN-1 (Compound 4b) is a dual VEGFR-2 and BRAF kinases inhibitor with IC₅₀ values of 0.049, 0.063 and 0.005 µM against VEGFR-2, BRAF ^V600E and BRAF ^WT, respectively. VEGFR-2/BRAF-IN-1 induces apoptosis and arrests the cell cycle mainly in the G1/S phase .

HY-151630

hCAIX-IN-16	Carbonic Anhydrase	Cancer
hCAIX-IN-16 (Compound 12d) is hCA IX inhibitor, with K_{i values of 190.0 and 187.9 nM for hCA IX and hCA XII, respectively. hCAIX-IN-16 can arrest the cell cycle of breast cancer MDA-MB-468 in G0-G1 and S phase and induce apoptosis. hCAIX-IN-16 shows good broad-spectrum anticancer activity and can be used for cancer research .}

HY-13721R

Phenoxodiol (Standard) Idronoxil (Standard); Dehydroequol (Standard); Haginin E (Standard)	Caspase Apoptosis Topoisomerase Reference Standards	Cancer
Phenoxodiol (Standard) is the analytical standard of Phenoxodiol. This product is intended for research and analytical applications. Phenoxodiol (Idronoxil), a synthetic analog of Genestein, activates the mitochondrial caspase system, inhibits XIAP (an apoptosis inhibitor), and sensitizes the cancer cells to Fas-mediated apoptosis. Phenoxodiol also inhibits DNA topoisomerase II by stabilizing the cleavable complex. Phenoxodiol induces cell cycle arrest in the G1/S phase of the cell cycle and upregulates p21WAF1 via a p53 independent manner .

HY-172111

EGFR-IN-144	EGFR Microtubule/Tubulin Interleukin Related TNF Receptor Apoptosis	Cancer
EGFR-IN-144 (Compound 4B) exhibits inhibitory activities against EGFR (IC₅₀=0.639 µg/mL) and tubulin polymerization (IC₅₀=7.339 µg/mL). EGFR-IN-144 exhibits cytotoxicity in multiple cancer cell with GI₅₀ of nanomolare levels. EGFR-IN-144 downregulates the expressions of mTOR, TNF-α, and IL-6, arrests the cell cycle at G1/S phase, and induces apoptosis .

HY-146200

PI3K/mTOR Inhibitor-8	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-8 (Compound 18b) is a PI3K and mTOR dual inhibitor with IC₅₀ values of 0.46 nM and 12 nM against PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-8 induces HCT-116 cells apoptosis and arrests cell cycle at the G1/S phase .

HY-172897

EGFR/DHFR-IN-2	EGFR Dihydrofolate reductase (DHFR) Apoptosis Cytochrome P450	Cancer
EGFR/DHFR-IN-2 (9b) is a dual h-DHFR/EGFR ^TK inhibitor, with IC₅₀ values of 0.192 μM and 0.109 μM for h-DHFR and EGFR, respectively. EGFR/DHFR-IN-2 (9b) halts the cell cycle at the G1/S phase and induces apoptosis. EGFR/DHFR-IN-2 (9b) is a potential inhibitor of CYP2C9 and CYP3A4. EGFR/DHFR-IN-2 (9b) can be used in the cancer research .

HY-149540

CTL-06	Fatty Acid Synthase (FASN)	Cancer
CTL-06 is an inhibitor of Fatty Acid Synthase (FASN) (IC₅₀: 3 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .

Cat. No.	Product Name	Target	Research Area